Stock AGRX AGILE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Agile Therapeutics, Inc.

Equities

AGRX

US00847L3087

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 03:03:20 2024-04-24 pm EDT 		5-day change 1st Jan Change
0.4003 USD +8.19% Intraday chart for Agile Therapeutics, Inc. +3.81% -79.47%
Mar. 28 Transcript : Agile Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024
Mar. 28 Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q4 Revenue $3.6M MT

Business Summary

Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Its initial product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on its proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Its potential product pipeline consists of two types of product candidates: a progestin-only (P-only) contraceptive patch and potential Twirla line extensions.

Number of employees: 19

Sales per Business

USD in Million2022Weight2023Weight Delta
Transdermal Patch
100.0 %
11 100.0 % 20 100.0 % +80.02%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
11 100.0 % 20 100.0 % +80.02%

Managers

Managers TitleAgeSince
Al Altomari CEO
 Chief Executive Officer 65 04-01-31
Scott Coiante DFI
 Director of Finance/CFO 57 10-11-30
Paul Korner CTO
 Chief Tech/Sci/R&D Officer 58 20-08-16
Geoffrey P. Gilmore ADM
 Chief Administrative Officer 58 14-07-31
Matthew Riley IRC
 Investor Relations Contact - 20-01-01
Amy Welsh PRN
 Corporate Officer/Principal 53 20-04-30
Kimberly Whelan PRN
 Corporate Officer/Principal - 19-11-30
Joseph D’Urso AUD
 Comptroller/Controller/Auditor - 14-09-30
Robert Conway PRN
 Corporate Officer/Principal 67 03-12-31

Members of the board

Members of the board TitleAgeSince
Al Altomari CEO
 Chief Executive Officer 65 04-01-31
Seth Fischer BRD
 Director/Board Member 68 16-07-27
John Hubbard BRD
 Director/Board Member 67 14-11-17
Sandra A. Carson BRD
 Director/Board Member 70 20-06-08
Josephine Torrente BRD
 Director/Board Member 58 21-10-06
Sharon Barbari BRD
 Director/Board Member 70 20-06-08

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 6,856,229 6,825,884 ( 99.56 %) 0 99.56 %
Stock B 0 4,850 0 4,850 ( 100.00 %)

Shareholders

NameEquities%Valuation
Armistice Capital LLC
1.575 %
108,000 1.575 % 36 720 $
Renaissance Technologies LLC
0.8634 %
59,200 0.8634 % 20 128 $
Al Altomari
0.6964 %
47,749 0.6964 % 16 235 $
Vanguard Group, Inc. (Subfiler)
0.2987 %
20,477 0.2987 % 6 962 $
Scott Coiante
0.2929 %
20,080 0.2929 % 6 827 $
Citadel Securities GP LLC
0.2807 %
19,247 0.2807 % 6 544 $
Geode Capital Management LLC
0.2005 %
13,748 0.2005 % 4 674 $
Robert Conway
0.1973 %
13,529 0.1973 % 4 600 $
Paul Korner
0.1969 %
13,500 0.1969 % 4 590 $
Amy Welsh
0.1969 %
13,500 0.1969 % 4 590 $

Company contact information

Agile Therapeutics, Inc.

500 College Road East Suite 310

08540-1715, Princeton

+609 683 1880

http://www.agiletherapeutics.com
address Agile Therapeutics, Inc.(AGRX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
AGILE THERAPEUTICS, INC. Stock Agile Therapeutics, Inc.
-79.47% 2.54M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.51% 105B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+3.22% 97.5B
ARGENX SE Stock argenx SE
+1.86% 22.19B
BIONTECH SE Stock BioNTech SE
-16.53% 21.33B
GENMAB A/S Stock Genmab A/S
-8.49% 18.68B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.33% 16.6B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.09% 14.52B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.47% 14.09B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.85% 10.99B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. AGRX Stock
  4. Company Agile Therapeutics, Inc.